A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma

Han, Xiaohong; Zhang, Mingzhi; Wang, Huaqing; Zhang, Qingyuan; Li, Wei; Hao, Miaowang; Gao, Yuhuan; Jin, Jie; Ren, Hanyun; Tang, Yongbai; Hong, Xin; Ke, Xiaoyan; Gui, Lin; Luo, Jun; Xie, Liangzhi; Gai, Wenlin; Shi, Yuankai

doi:10.21147/j.issn.1000-9604.2022.06.08

Chinese Journal of Cancer Research

2022

DOI: 10.21147/j.issn.1000-9604.2022.06.08

|View full text |Cite

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma

Xiaohong Han¹,

Mingzhi Zhang²,

Huaqing Wang³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma

Cited by 1 publication

References 17 publications

Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases

Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases

Contact Info

Product

Resources

About